ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Corcept Therapeutics, Inc. ?
1
High Management Efficiency with a high ROE of 21.09%
2
Company has a low Debt to Equity ratio (avg) at times
3
Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 21.09%
4
Negative results in Sep 25
- PRE-TAX PROFIT(Q) At USD 15.24 MM has Fallen at -51.69%
- ROCE(HY) Lowest at 16.47%
- NET PROFIT(Q) Lowest at USD 19.36 MM
5
With ROE of 20.76%, it has a very expensive valuation with a 13.75 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -38.65%, its profits have risen by 5.6% ; the PEG ratio of the company is 15.6
6
High Institutional Holdings at 80.97%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
7
Below par performance in long term as well as near term
- Along with generating -38.65% returns in the last 1 year, the stock has also underperformed S&P 500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Corcept Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Corcept Therapeutics, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Corcept Therapeutics, Inc.
-38.65%
0.05
134.92%
S&P 500
17.78%
0.92
19.35%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
15.79%
EBIT Growth (5y)
-13.15%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.47
Sales to Capital Employed (avg)
1.01
Tax Ratio
1.56%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
83.87%
ROCE (avg)
111.37%
ROE (avg)
21.09%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
66
Industry P/E
Price to Book Value
13.75
EV to EBIT
82.40
EV to EBITDA
80.90
EV to Capital Employed
28.52
EV to Sales
11.73
PEG Ratio
15.62
Dividend Yield
NA
ROCE (Latest)
34.61%
ROE (Latest)
20.76%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend5What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 162.85 MM
RAW MATERIAL COST(Y)
Fallen by 0.66% (YoY
INVENTORY TURNOVER RATIO(HY)
Highest at 1.31 times
NET SALES(Q)
Highest at USD 207.64 MM
-14What is not working for the Company
PRE-TAX PROFIT(Q)
At USD 15.24 MM has Fallen at -51.69%
ROCE(HY)
Lowest at 16.47%
NET PROFIT(Q)
Lowest at USD 19.36 MM
EPS(Q)
Lowest at USD 0.16
Here's what is working for Corcept Therapeutics, Inc.
Operating Cash Flow
Highest at USD 162.85 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
Highest at USD 207.64 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Inventory Turnover Ratio
Highest at 1.31 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Raw Material Cost
Fallen by 0.66% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Corcept Therapeutics, Inc.
Pre-Tax Profit
At USD 15.24 MM has Fallen at -51.69%
over average net sales of the previous four periods of USD 31.55 MMMOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (USD MM)
Net Profit
At USD 19.36 MM has Fallen at -41.33%
over average net sales of the previous four periods of USD 32.99 MMMOJO Watch
Near term Net Profit trend is very negative
Net Profit (USD MM)
Net Profit
Lowest at USD 19.36 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is negative
Net Profit (USD MM)
EPS
Lowest at USD 0.16
in the last five periodsMOJO Watch
Declining profitability; company has created lower earnings for shareholders
EPS (USD)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
